Business development partnerships

We are actively seeking strategic partners that align with our vision. We are interested in partnering worldwide rights to the following pre-commercial and commercial assets: 

1.  A-101 45% Topical Solution, our investigational drug candidate for common warts;

2. ATI-501 oral and ATI-502 topical Janus Kinase (JAK) 1/3 inhibitors, our investigational drug candidates for the potential treatment of alopecia; and 

3. ESKATA® (hydrogen peroxide) topical solution, 40% (w/w), our FDA-approved product for the treatment of seborrheic keratoses that are raised.  

Learn more about ESKATA®

Prescribing Information »


We are actively seeking research and licensing partners to fully leverage the transformational potential of our KINectTM Platform for drug discovery. Specific areas of interest include:

  • Kinase inhibitors for autoimmune diseases, such as rheumatoid arthritis, diseases of chronic inflammation, such as COPD, and cancer, particularly breast, colon, and pancreatic cancer
  • New therapeutic applications of our cysteinome-targeted chemical library representing 60% of the kinome

Learn more about the KINectTM platform

If you wish to inquire about investigator-initiated studies, find out more.